A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Inclusion Criteria:

• Subject has agreed to participate by providing written informed consent.

• Subject will be eligible to participate if one of the following criteria is met:

• Subject has completed the 28-week double-blind phase of study D1050238

• Subject has experienced a protocol-defined relapse event during the double- blindphase in study D1050238

• Subject is participating in the open-label or double-blind phase of study D1050238if/when study D1050238 is terminated by the sponsor.

• Subject has completed all required assessments on the final study visit (Study VisitNumber 42) in study D1050238.

• Subject is judged by the Investigator to be suitable for participation in a 12-weekclinical trial involving open-label lurasidone treatment and is able to comply withthe protocol in the opinion of the Investigator.

Exclusion Criteria:

• Subject is considered by the investigator to be at imminent risk of suicide or injuryto self, others, or property.

• Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation withsome intent to act, without specific plan) or item 5 (active suicidal ideation withspecific plan and intent) on the C-SSRS at the extension baseline visit (Study VisitNumber 42 in study D1050238). Subjects who answer "yes" to this question must bereferred by the Investigator for appropriate follow-up evaluation and treatment.

• Subject tests positive for drugs of abuse or is suspected of current alcohol abuse atthe extension baseline visit (Study Visit Number 42 in study D1050238). In the event asubject tests positive for cannabinoids, the Investigator will evaluate the subject'sability to abstain from cannabis during the study.